The Lancet Diabetes & Endocrinology

The Lancet Diabetes & Endocrinology is a monthly peer-reviewed medical journal covering diabetes, endocrinology and metabolism, launched in 2013 as a specialty title of the Lancet family and published by Elsevier, with a 2025 Journal Impact Factor of 36.3《柳叶刀：糖尿病与内分泌学》是一本同行评审的月度医学期刊，涵盖糖尿病、内分泌学与代谢，2013 年作为《柳叶刀》家族的专科刊创办，由（Elsevier）出版，2025 年影响因子为 36.3。

Scope

• It provides a global, authoritative and independent forum for high-impact clinical research and opinion covering all aspects of endocrinology, diabetes and metabolism该刊为内分泌学、糖尿病与代谢各领域的高影响力临床研究与观点提供具全球视野的权威独立论坛。
• Topics include diabetes, obesity, nutrition and metabolism, osteoporosis, adrenal disorders and bone metabolism报道主题包括糖尿病、肥胖、营养与代谢、骨质疏松、肾上腺疾病与骨代谢。
• It also covers growth disorders, lipid disorders, neuroendocrinology, paediatric endocrinology, pituitary disorders, reproductive endocrinology and thyroid disorders该刊还涵盖生长障碍、脂质紊乱、神经内分泌学、儿科内分泌学、垂体疾病、生殖内分泌学与甲状腺疾病。
• It runs a fast-track service under which peer-reviewed research papers can be published online within eight weeks of submission该刊设快速通道，经同行评审的研究论文可在投稿后八周内在线发表。
• It publishes original research, expert reviews and candid commentary that offer an independent perspective on practice-changing research该刊刊载原创研究、专家综述与坦率评论，就改变临床实践的研究提供独立视角。
• Its pages also carry news, views and policy analysis aimed at key opinion leaders across medicine, government and health systems其版面还刊载面向医学界、政府与卫生系统意见领袖的新闻、观点与政策分析。
• As a Lancet specialty journal it shares the editorial standards and peer-review practice of The Lancet family作为《柳叶刀》专科刊，它沿用《柳叶刀》家族的编辑标准与同行评审做法。

History

• It was launched in print and online in September 2013, after a preliminary preview issue appeared in June 2013该刊于 2013 年 9 月以印刷版与在线版同步推出，此前在 2013 年 6 月出过一期试刊。
• It is one of the specialty titles in the Lancet family alongside The Lancet Oncology, The Lancet Respiratory Medicine and others, while the parent journal The Lancet dates from 1823它是《柳叶刀》家族中的专科刊之一，同族还有（The Lancet Oncology）与（The Lancet Respiratory Medicine）等，而母刊《柳叶刀》创办于 1823 年。
• Justine Davies served as an editor-in-chief of the journal in its early yearsJustine Davies 曾在该刊早期担任主编。
• Its Journal Impact Factor stood at 41.8 in 2024 and 36.3 in 2025, ranking third among 198 endocrinology and metabolism titles其影响因子 2024 年为 41.8、2025 年为 36.3，在内分泌与代谢类别 198 种期刊中排名第三。^[1]
• The journal belongs to the Lancet Group of titles published by Elsevier, which has owned the parent title The Lancet since 1991该刊隶属（Elsevier）出版的《柳叶刀》刊群，后者自 1991 年起持有母刊《柳叶刀》。
• According to Elsevier media information the journal is now published online only, having begun as a simultaneous print and online title据（Elsevier）媒体资料，该刊现以在线形式发行，创办之初则为印刷与在线同步。

Editors

• The editor-in-chief is Rob Brierley, according to Elsevier's journal media information据（Elsevier）期刊媒体资料，现任主编为 Rob Brierley。
• Rob Brierley previously served as deputy editor of The Lancet Oncology within the same publisherRob Brierley 此前在同一出版方旗下的（The Lancet Oncology）担任副编辑。
• Justine Davies was an earlier editor-in-chief of the journalJustine Davies 是该刊更早时期的一位主编。
• Editorial decisions are made in-house, with commissioning, peer review and revision managed by the journal's own editors编辑决定由该刊内部作出，约稿、同行评审与修回均由本刊编辑统筹。
• It forms part of the Lancet Group, whose editors share a common editorial and peer-review approach across the specialty titles该刊属《柳叶刀》刊群，其编辑在各专科刊之间共用一套编辑与同行评审方法。